Gyre Therapeutics (GYRE) Times Interest Earned (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Times Interest Earned of -$11.08 for Q1 2026, down 409.65% year-over-year from $3.58 in Q1 2025, and down 2514.08% quarter-over-quarter from $0.46 in Q4 2025.
Gyre Therapeutics (GYRE) Times Interest Earned (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Times Interest Earned for 15 consecutive years, with -$11.08 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned fell 409.65% year-over-year to -$11.08; the TTM figure through Mar 2026 stood at -$0.17 (down 101.02% YoY), while the FY2025 annual figure was $0.13, up 52.73% from the prior year.
- Times Interest Earned retreated to -$11.08 in Q1 2026 per GYRE's latest filing, from $0.46 in the prior quarter.
- Across five years, Times Interest Earned topped out at $105.49 in Q3 2023 and bottomed at -$861.0 in Q3 2022.
- Historically, Times Interest Earned has averaged -$66.61 across 5 years, with a median of $2.22 in 2024.
- On a YoY basis, Times Interest Earned climbed as much as 636.23% in 2022 and fell as far as 8349.94% in 2022.
- Gyre Therapeutics' Times Interest Earned stood at $24.82 in 2022, then slumped by 1866.61% to -$438.43 in 2023, then jumped by 100.63% to $2.76 in 2024, then sank by 83.36% to $0.46 in 2025, then slumped by 2514.08% to -$11.08 in 2026.
- Business Quant data shows GYRE's Times Interest Earned at -$11.08 in Q1 2026, $0.46 in Q4 2025, and $5.72 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -3.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.35 |
| Mar 31, 2026 | -11.08 |
| Dec 31, 2025 | 0.46 |
| Sep 30, 2025 | 5.72 |
| Jun 30, 2025 | 1.49 |
| Mar 31, 2025 | 3.58 |
| Dec 31, 2024 | 2.76 |
| Sep 30, 2024 | 2.22 |
| Jun 30, 2024 | 1.53 |
| Mar 31, 2024 | 25.62 |
| Dec 31, 2023 | -438.43 |
| Sep 30, 2023 | 105.49 |
| Jun 30, 2023 | -12.44 |
| Mar 31, 2023 | 10.36 |
| Dec 31, 2022 | 24.82 |
| Sep 30, 2022 | -861.00 |
| Jun 30, 2022 | 35.81 |
| Mar 31, 2022 | -29.28 |
| Dec 31, 2021 | -30.59 |
| Sep 30, 2021 | -10.19 |